Abstract TP311: Preclinical Replication Study of Psd-95 Inhibitor NA-1

Ha Kim,Seungbum Choi,Dong-Eog Kim

DOI: https://doi.org/10.1161/str.55.suppl_1.tp311

IF: 10.17

2024-02-01

Stroke

Abstract:Background & Objective: Nerinate (NA-1), a postsynaptic density protein-95 inhibitor, is a clinical-stage stroke neuroprotectant. Recently, in a phase-III clinical trial (Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke [ESCAPE-NA1]), a single intravenous dose of NA-1 did not improve the proportion of patients achieving favorable 3-month functional outcomes after endovascular thrombectomy compared with patients receiving placebo. Thus, we conducted a preclinical replication study to test therapeutic efficacy of NA-1 in a mouse model of transient middle cerebral artery occlusion (tMCAO). Methods: After 30-minute or 60-minute MCAO with laser Doppler flowmetry (LDF) monitoring, mice were randomly assigned to a group treated with either vehicle control (n=10 and 21, respectively) or 10 nM/g NA-1 (n=10 and 21, respectively), which was intravenously administered once via penile vein in a volume of 200 μL at the beginning of recanalization. In a different set of mice (n=6 for vehicle and n=6 for NA-1), we performed MCAO and then allowed animals to wake up before reperfusion at 60 minutes to account for continuous anesthesia-related confounding. At 1-day poststroke, brain was harvested and sliced in 2-mm thickness for 2,3,5-triphenyl-tetrazolium chloride (TTC) staining and infarct volume measurement after neurological scoring. Results: LDF data indicated that stroke modeling was executed proficiently, without inter-group differences. The vehicle group and the NA-1 group showed similar infarct volumes at 1 day after either 30 minutes (32.5±6.4 mm 3 and 44.7±8.7 mm 3 ; t-test P =0.27) or 60 minutes of MCAO (113.4±7.6 mm 3 and 108.2±7.6 mm 3 ; P =0.63). Awakening between occlusion and reperfusion did not change the negative Results: 109.4±11.7 mm 3 and 115.8±10.6 mm 3 ( P =0.69). Neurological scores did not show significant inter-group differences, either (all P >0.05). Conclusions: We were unable to reproduce neuroprotective effects of NA-1 to reduce infarct volume at 1 day after tMCAO for 30 or 60 minutes. We suggest that implementation of multicenter animal studies is warranted to enhance the reproducibility and generalizability of preclinical observations.

peripheral vascular disease,clinical neurology